Our team consists of experienced study coordinators, highly experienced Principal and Associate Investigators and a dedicated Research Fellow. Our team actively participates in investigator lead research, national and international clinical trials in Endoscopy, Hepatology and Inflammatory Bowel Disease.
Current Recruiting Trials:
AMETRINE 2 – GA45330: A Phase 3, multicenter, double-blind, placebo-controlled study to assess the efficacy and safety of induction therapy with RO7790121 in patients with moderately to severely active Ulcerative Colitis Sponsor: Roche Principal Investigator: Dr Elizabeth Chow
CHROMA CD- DRI18450: A Phase 2, multicenter, randomized, double-blind, placebo controlled, dose ranging study to evaluate the efficacy and safety of SAR442970 in adults with moderate to severe Chrohn’s disease Commercial Sponsor: SANOFI Aventis Principal Investigator: A/Prof Elizabeth Chow.
RESTORE – ISI-ROM-001-2024: A Prospective Investigation of the Feasibility and Safety of Duodenal Mucosal Regeneration for Type 2 Diabetes Mellitus Using Endoscopic Ablation Sponsor: Ascend Principal Investigators: Dr Alan Moss and Dr Dev Kevat
SIBERITE-2- GA45332: A Phase 3, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of induction therapy with RO7790121 in patients with moderately to severely active Chrohn’s disease Commercial Sponsor: ROCHE Principal Investigator: Dr Elizabeth Chow
TAK-279-UC-2001: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-blind induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severe Active Ulcerative Colitis Commercial Sponsor: TAKEDA Principal investigator: Dr Ian Kronborg
TAK-279-CD-2001: A Phase 2b, Multicenter, Randomized, Double-Blind induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severe Active Chrohn’s Disease Commercial Sponsor: TAKEDA Principal investigator: Dr Ian Kronborg
Current Active Clinical Trials:
CULTIVATE: A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease Commercial Sponsor: Arena Pharmaceuticals Principal Investigator: A/Prof Elizabeth Chow
QUASAR: A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis (QUASAR) Commercial Sponsor: Janssen Research & Development, LLC. Principal Investigator: A/Prof Elizabeth Chow.
Page last updated November 2025
